Clinical Scorecard: FDA Approves Odactra for Pediatric House Dust Mite Allergy

At a Glance

Key Highlights

• Odactra is now approved for children aged 5 to 11 with house dust mite-induced allergic rhinitis.
• The decision was based on the MT-12 phase III trial involving 1,460 pediatric patients.
• House dust mites are a leading cause of respiratory allergic disease.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of house dust mite allergy in pediatric patients.

Management

• Consideration of Odactra as a treatment option for pediatric patients.

Monitoring & Follow-up

• Monitor efficacy and safety in pediatric patients receiving Odactra.

Risks

• Potential risks associated with sublingual immunotherapy.

Patient & Prescribing Data

Pediatric patients aged 5 to 11 years with house dust mite allergy.

Odactra provides an additional treatment option for this population.

Clinical Best Practices

• Utilize evidence from the MT-12 trial for treatment decisions.
• Ensure proper diagnosis before initiating immunotherapy.

Related Resources & Content

• FDA Approval Announcement
• MT-12 Trial Publication